Demonstrated high-affinity binding to human Parkinson’s disease-brain derived alpha-synuclein
Potentially first diagnostic for detecting and monitoring Parkinson’s disease
Further reinforces productivity of MorphomerTM drug discovery platform
The data, presented by AC Immune’s
The Morphomer a-syn PET tracer, which is entering clinical trials for the imaging of pathological a-syn in Parkinson’s disease (PD) and other synucleinopathies, was derived from AC Immune’s proprietary small molecule Morphomer discovery platform. The company also is beginning preclinical development of oral small molecule Morphomer a-syn inhibitors and SupraAntigenTM a-syn antibodies as novel therapeutic candidates to treat PD and a-syn-related NeuroOrphan diseases.
Development of a selective a-syn PET tracer would allow for earlier diagnosis and disease tracking. And it could transform drug development, offering an objective and efficient outcome measure to evaluate disease-modifying therapies, which remain the greatest unmet need of the millions living with Parkinson’s disease.
The Morphomer discovery platform has recently been validated by a global partnership agreement with
Progressive accumulation of aggregated a-syn in the form of Lewy bodies and neurites is the pathognomonic hallmark of PD.
AC Immune’s Morphomer platform enables identification of a new class of low molecular weight compounds via rational chemical design that enables generation of small molecules, called Morphomers, which bind with high specificity to misfolded proteins, working to break up neurotoxic aggregates and inhibit aggregation and seeding. Other key CNS drug features of Morphomers include brain penetration, bioavailability and metabolic stability.
The PET tracer data was one of several presentations by
- Determination of the optimal scanning time for the assessment of Tau deposition in Alzheimer’s disease using PI-2620 PET
- Small molecules targeting Tau propagation demonstrate efficacy in an aggressive tauopathy mouse model
- Discovery and development of diagnostics and therapeutics for TDP-43 proteinopathies
- Determination of the optimal scanning time for the assessment of Tau deposition in Alzheimer's Disease using PI-2620 PET
- 18F-PI-2620 Tau-PET in progressive supranuclear palsy - a multi-center evaluation
- Evaluation of Tau deposition in amyloid positive MCI or mild-AD dementia subjects from the elenbecestat MissionAD program using 18F-PI-2620 PET
For further information, please contact:
AC Immune Investor Relations
Phone: +1 970 987 2654
Phone: +1 617 792 3937
|European Investors & Media
Phone: +41 79 367 6254
Forward looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the